Results 11 to 20 of about 1,913 (212)
Case Reports in Ophthalmological Medicine, 2022 Purpose. To describe an alternative treatment for a patient with serpiginous choroiditis (SC) who was not tolerant to systemic therapies. Methods. Case report of a patient with serpiginous choroiditis with their clinical course followed with ophthalmic ...
Yousuf Siddiqui +4 more
doaj +4 more sources
Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review [PDF]
Journal of Ophthalmology, 2021 Corticosteroids are used in a variety of ophthalmological diseases. One challenge faced by ophthalmologists is to deliver corticosteroids to the posterior segment of the eye with efficacy and safety.
Flávio Ribeiro, Manuel S. Falcão
doaj +4 more sources
Scleral melt following Retisert intravitreal fluocinolone implant
Drug Design, Development and Therapy, 2014 Ilias Georgalas,1 Chrysanthi Koutsandrea,1 Dimitrios Papaconstantinou,1 Dimitrios Mpouritis,1 Petros Petrou1,2 1Ophthalmology Department, University of Athens, Athens, Greece; 2Moorfields Eye Hospital, London, UKAbstract: Intravitreal fluocinolone ...
Georgalas I +4 more
doaj +7 more sources
Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
Drug Design, Development and Therapy, 2013 Wyatt B Messenger, Robert M Beardsle, Christina J FlaxelCasey Eye Institute, Oregon Health and Science University, Portland, OR, USAAbstract: Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser
Messenger WB, Beardsley RM, Flaxel CJ
doaj +6 more sources
Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the Treatment of Retinal Conditions. A Review of Clinical Studies [PDF]
Drug Design, Development and Therapy, 2023 Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non– infectious ...
Georgios D Panos +5 more
core +5 more sources
Evaluation of fluocinolone acetonide 0.19 mg intravitreal implant in the management of birdshot retinochoroiditis [PDF]
British Journal of Ophthalmology, 2020 Purpose: To report treatment outcomes and efficacy of the fluocinolone acetonide 0.19 mg intravitreal implant (Iluvien) in controlling retinal and choroidal inflammation in 11 patients with birdshot retinochoroiditis.
Ajamil-Rodanes, S +5 more
core +5 more sources
Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review [PDF]
Journal of International Medical Research, 2019 Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti ...
Horace Massa +5 more
doaj +5 more sources
Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy. [PDF]
PharmacotherapyABSTRACT Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing ...
Clements JN, Mesawich J, Twisdale C.
europepmc +2 more sources
Acta Ophthalmologica, Volume 101, Issue 1, Page 22-33, February 2023., 2023 Abstract Purpose To evaluate topical dexamethasone ophthalmic suspension OCS‐01 (Oculis SA, Lausanne, Switzerland) in diabetic macular edema (DME). Methods This was a multicenter, double‐masked, parallel‐group, randomized, Phase 2 study. Patients aged 18–85 years with DME of <3 years duration, ETDRS central subfield thickness ≥ 310 μm by SD‐OCT, and ...
Einar Stefansson +8 more
wiley +1 more source
Diabetic Macular Oedema Guidelines: An Australian Perspective
Journal of Ophthalmology, Volume 2023, Issue 1, 2023., 2023 The number of people living with diabetes is expected to rise to 578 million by 2030 and to 700 million by 2045, exacting a severe socioeconomic burden on healthcare systems around the globe. This is also reflected in the increasing numbers of people with ocular complications of diabetes (namely, diabetic macular oedema (DMO) and diabetic retinopathy ...
Yew Sen Yuen +15 more
wiley +1 more source